Cancer progression relies on escaping the immune system.

To counter this, scientists developed custom-engineered chimeric antigen receptors (CARs) to improve the effectiveness of therapeutic attempts to track and eliminate cancer cells. However, immune evasion still causes significant disease resistance and relapse.

In response to these challenges, A. Schmidt et al. leveraged our Single-Cell Functional Proteomics to create a new CAR capable of binding multiple antigens.

Download this Paper Summary to learn more!